FIGURE

Fig. 2

ID

ZDB-FIG-240202-2

Publication

Larsson et al., 2024 - Repurposing proteasome inhibitors for improved treatment of triple-negative breast cancer

Other Figures

All Figure Page

Back to All Figure Page

Fig. 2

All eleven proteasome inhibitors were tested for their ability to inhibit the activity at the β5 proteasome site.

Bortezomib and delanzomib show 95% and 55% inhibition at 1000 nM, and at 10000 nM they inhibit activity to 100% while MLN-9708 (51%), MLN-2238 (33%), and MG-132 (25%) inhibit the β5 site to a small extent. Statistically significant differences in the suppression of chymotrypsin-like activity in the proteasome between various doses of proteasome inhibitor were determined using the paired t-test. *P < 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001.

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Cell Death Discov